About Nebula Genomics
Nebula Genomics is a Healthcare company based in San Francisco (United States) founded in 2016 by George M Church, and was acquired by ProPhase Labs in August 2021. DNA sequencing technology for personal genomics is developed. It operates on a Direct-to-Consumer (D2C) and Subscription Services model. Nebula Genomics has raised $4.3 million across 1 funding round from investors including Khosla Ventures, Arch Venture Partners and ProPhase Labs. The company has 2 employees. Its website nebula.org draws about 190 thousand monthly visits. Nebula Genomics offers products and services including 30x Whole Genome Sequencing and 100x Whole Genome Sequencing. Its focus areas include Biotechnology and Genomics. Its legal entity is NEBULA GENOMICS, INC. Its competitors include Helix, Benchling and BioAge Labs; 3 of its 3 listed competitors have raised funding.
Company details
Whole genome sequencing is offered by Nebula Genomics to decode 100 of DNA for health and ancestry insights. Services are focused on personal genomics, covering sectors like healthcare and biotechnology. Advanced DNA testing solutions, including 30x and 100x coverage, are provided for comprehensive genetic analysis. Privacy protection technology is integrated to secure genomic data. Partnerships with academic and research institutions are maintained to enhance genomic research applications.
- Headquarters San Francisco, United States
- Employees 2
- Founders George M Church
- Stage Acquired
- SectorsHealthcare
- Website category Health
- Email••••••••
- Website nebula.org
- Social LinkedIn X Facebook Instagram
- Acquired by ProPhase Labs (Aug 2021)
- Legal Name Nebula Genomics, Inc.
- Total Equity Funding$4.3M (USD)
in 1 rounds
- Latest Funding Round$4.3M (USD), Seed
Aug 2018
- InvestorsKhosla Ventures
& 11 more
- Employee Count2
- Acquired byProPhase Labs
(Aug 2021)
Products & Services of Nebula Genomics
Nebula Genomics offers a comprehensive portfolio of products and services, including 30x Whole Genome Sequencing and 100x Whole Genome Sequencing.
Entire genome is sequenced at 30x coverage depth.
Entire genome is sequenced at 100x coverage depth.
Funding Insights of Nebula Genomics
Nebula Genomics has successfully raised a total of $4.3M through 1 strategic funding round. The most recent funding activity was a Seed round of $4.3 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.3M
- Total Rounds 1
- Last Round Seed — $4.3M
- First Round $4.3M
(Aug 2018)
- Investors Count 11
All 1 funding rounds of Nebula Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2018 | $4.3M | Seed | – | Khosla Ventures, Fenbushi Capital | – |
12 investors in total: 12 institutional.
Investors in Nebula Genomics
Nebula Genomics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Khosla Ventures, Arch Venture Partners and ProPhase Labs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Early-stage venture capital firm investing in the US and UK | fenbushi.vc | Shanghai, China | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Mayfield is focused on AI innovation and venture capital investments. | mayfield.com | Menlo Park, United States | ||
Early-stage startups in emerging technologies are funded by Hemi Ventures. | 2019 | hemi.vc | Palo Alto, United States | |
Telemedicine services are provided via an online digital health platform. | 2017 | heartbeatlabs.com | Berlin, Germany | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors | gpv.com | San Francisco, United States | ||
Hikma Ventures is focused on digital health investments. | 2015 | hikmaventures.com | London, United Kingdom | |
Venture capital investment firm based out of South Korea | venture.miraeasset.com | Seoul, South Korea |
Investor details for Nebula Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nebula Genomics
3 people are tracked at Nebula Genomics (3 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
George M Church | Co-Founder | Leadership |
Kamal Obbad | CEO, Co-founder | Leadership |
Kevin Quinn | Chief Product Officer | Leadership |
Complete people profiles for Nebula Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nebula Genomics
3 dated milestones of Nebula Genomics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Nebula Genomics is founded.
- Funding First funding round of $4.3M.
- Exit Acquired by ProPhase Labs.
Competitors of Nebula Genomics
Nebula Genomics has 3 listed competitors in our database, 3 of them funded. They include Helix, Benchling and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of Nebula Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nebula Genomics
The website of Nebula Genomics (nebula.org) receives about 190K visits a month and ranks #244,937 among all websites worldwide, #8,218 in Health.
- Monthly visits190K
▲ 11.5% vs previous month
- Unique visitors75.8K
per month
- Global rank#244,937
among all websites
- Category rank#8,218
Health · Health
- Bounce rate41%
- Pages per visit2.2
- Average visit50 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Nebula Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sequencing.com | 100% | 707.8K | #58,012 | View details | |
plexaderm.com | plexaderm.com | 93% | #263,111 | – | |
| mygenetics.ru | 88% | 112K | #330,248 | View details | |
dailyhealthsupplement.com | dailyhealthsupplement.com | 88% | #4,653,062 | – | |
| genotek.ru | 88% | 2.2M | #19,931 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Nebula Genomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Nebula Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nebula Genomics
Complete news archive for Nebula Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nebula Genomics
Nebula Genomics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Nebula Genomics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Nebula Genomics is a funded company, having raised a total of $4.3M across 1 funding round to date. The company's 1st funding round was a Seed of $4.3M, raised on Aug 2018.
Nebula Genomics has 2 employees.
Whole genome sequencing is offered by Nebula Genomics to decode 100 of DNA for health and ancestry insights. Services are focused on personal genomics, covering sectors like healthcare and biotechnology. Advanced DNA testing solutions, including 30x and 100x coverage, are provided for comprehensive genetic analysis. Privacy protection technology is integrated to secure genomic data. Partnerships with academic and research institutions are maintained to enhance genomic research applications.
Nebula Genomics's top competitors include Helix, Benchling and BioAge Labs.
Nebula Genomics offers 30x Whole Genome Sequencing and 100x Whole Genome Sequencing.
Nebula Genomics has 12 investors. Key investors include Khosla Ventures, Arch Venture Partners, ProPhase Labs, Heartbeat Labs, and Fenbushi Capital.
Nebula Genomics operates through Nebula Genomics, Inc..
Yes. Nebula Genomics was acquired by ProPhase Labs in August 2021.
The website of Nebula Genomics receives about 190 thousand visits a month and ranks #244,937 among all websites worldwide.